CorMedix Inc.  

(Public, NYSEMKT:CRMD)   Watch this stock  
Find more results for CRMD
3.55
-0.19 (-5.08%)
Jul 2 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 3.20 - 3.79
52 week 1.25 - 10.40
Open 3.79
Vol / Avg. 1.16M/1.13M
Mkt cap 109.93M
P/E     -
Div/yield     -
EPS -0.42
Shares 31.05M
Beta -1.24
Inst. own 13%
May 8, 2015
Q1 2015 CorMedix Inc Earnings Call
May 7, 2015
Q1 2015 CorMedix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -17586.92% -10806.48%
Operating margin -17584.55% -6004.50%
EBITD margin - -4695.44%
Return on average assets -296.99% -507.18%
Return on average equity -395.11% -
Employees 5 -
CDP Score - -

Address

1430 US Highway 206 Ste 200
BEDMINSTER, NJ 07921-4602
United States - Map
+1-908-5179500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company's primary product is Neutrolin, a catheter lock solution, which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. It has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC, a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin, which is in the pre-clinical stage of development.

Officers and directors

Cora M. Tellez Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Randy Milby Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Harry O'Grady Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Antony E. Pfaffle M.D. Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Matthew P. Duffy Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael W. George Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven W. Lefkowitz Independent Director
Age: 59
Bio & Compensation  - Reuters
Taunia S. Markvicka Pharm.D. Independent Director
Age: 46
Bio & Compensation  - Reuters